"Enhancing patient care for people with schizophrenia is something we strive for every day as physicians treating this illness," said Andreas Heinz, M.D., Director, Department of Psychiatry, Charite University Medical Center, Berlin. "We hope more options become available to meet the needs of patients with this complex and debilitating disease."
Recently, Janssen-Cilag International NV has submitted a Marketing Authorization Application to the European Medicines Evaluations Agency (EMEA) for this drug whose trade name for marketing hasn’t been determined yet.
Read more at PR Newswire.
.jpg)
Comment Preview